Intuitive Surgical

ISRG

Market cap $150B

Intuitive Surgical's stock is trading near 52-week lows. The stock is down 30% from its most recent high-water mark.

Jensen Huang keeps quoting a $40 trillion humanoid robot TAM, and the market is rewarding every concept video and 2030 roadmap that mentions the word robot.

Current Chief Commercial and Marketing Officer Henry Charlton to become SVP of Global Business Operations Current Chief Commercial and Marketing Officer Henry Charlton to become SVP of Global Business Operations

Intuitive Surgical (ISRG) is well positioned to outperform the market, as it exhibits above-average growth in financials.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

ISRG is widening its robotic surgery lead with faster growth, rising procedures and a recurring revenue model as Medtronic builds Hugo.

ISRG's Ion platform saw 39% procedure growth in Q1, with new clinical data strengthening its role in lung cancer diagnosis.

GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.

Intuitive Surgical (ISRG) reported earnings 30 days ago. What's next for the stock?

Intuitive Surgical's ISRG single-port (SP) platform emerges as one of its most intriguing long-term growth opportunities, though the key question remains whether it can unlock incremental total addressable market (TAM) or simply serve as a substitution within existing robotic procedures.